First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is an effective treatment for advanced lung cancer harboring EGFR gene mutations, and has improved progression-free survival in several clinical trials. METHODS: We investigated 30 stage I non-small-cell lung can...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhouyu, Chai, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899306/
https://www.ncbi.nlm.nih.gov/pubmed/33628055
http://dx.doi.org/10.2147/CMAR.S292295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899306/
https://www.ncbi.nlm.nih.gov/pubmed/33628055
http://dx.doi.org/10.2147/CMAR.S292295

Ejemplares similares